Scaling a Biotech Startup: The Unicycive Therapeutics Playbook for B2B Growth in Healthcare

Introduction: When Science Meets Strategy

In the high-stakes world of biotech, where clinical trials can make or break a company, scaling a business requires more than just breakthrough science. It demands a ruthless focus on go-to-market (GTM) execution, clear messaging, and operational discipline. This is the exact challenge that Shalabh Gupta, M.D., Founder, Chairman, and CEO of Unicycive Therapeutics, has tackled head-on.

In a recent conversation with Moira Forbes, Forbes EVP and Forbes Women President, Dr. Gupta shared the strategic playbook behind Unicycive’s growth. While the interview covered the company’s mission in renal disease treatments, the underlying B2B lessons are universal for any SaaS or tech revenue team looking to scale effectively.

At B2B Pulse, we believe the best growth stories come from outside the echo chamber of software. Biotech, with its regulatory hurdles, long sales cycles, and high-stakes funding, offers a masterclass in GTM rigor. Here’s how Dr. Gupta’s insights translate into actionable strategies for your revenue team.

The Founder’s Dilemma: From Scientist to CEO

The Reality of Wearing Two Hats

Dr. Gupta didn’t just start Unicycive Therapeutics; he built it from the ground up. As a physician-scientist, his primary expertise was in understanding the biological mechanisms behind chronic kidney disease. But as CEO, he had to become a salesperson, a strategic marketer, and a storyteller all in one.

This is a common struggle in B2B tech. Founders often emerge from product or engineering, not sales. They know the technical specs inside out, but struggle to translate that into compelling value propositions for buyers. The lesson here is clear: Your technical depth is an asset, but only if you can bridge it to business outcomes.

For Unicycive, that meant focusing on a very specific pain point: the unmet need for better phosphate-lowering therapies in dialysis patients. For your SaaS or tech company, it means identifying the single biggest revenue blocker your ICP faces and building your entire GTM motion around solving it.

Key Takeaway for Revenue Teams

Don’t let the product lead the conversation. Lead with the problem your product solves.
Founders should invest time in sales enablement. Even if you’re not a VP of Sales, your vision will inspire trust in buyers.

The Unicycive Playbook: 3 GTM Principles for Scaling a Niche Market

Principle 1: Dominate Your ICP Before Expanding

Unicycive didn’t try to treat every kidney disease at once. They zeroed in on a specific, underserved patient population—those with end-stage renal disease and hyperphosphatemia. This is the classic “land and expand” strategy, but executed with surgical precision.

In B2B sales, your ICP (Ideal Customer Profile) is your dialysis center. You don’t need to be everything to everyone. Pick a vertical, a use case, or a company size, and become the go-to solution for that specific pain point.

Actionable Steps:

Audit your existing customers. Identify the common thread that makes them successful and profitable.
Build a “Perfect Customer” scorecard. Rate leads against your ICP to avoid wasting resources on bad fits.
Develop case studies from your niche wins. Niche dominance creates social proof faster than broad market claims.

Principle 2: Use Clinical Outcomes as Revenue Data

In biotech, revenue is tied to clinical outcomes. For Unicycive, that means FDA approvals and trial results. For your SaaS, that means customer success metrics like retention rate, upsell, and NPS.

Dr. Gupta’s strategy? Make the data tell a story. He didn’t just talk about the drug’s mechanism; he framed it in terms of patient outcomes. Similarly, your sales team should not just pitch features; they should present case studies that show real ROI, time-to-value, and churn reduction.

How to Apply It:

Turn customer success data into a playbook. If your best customers achieve 3x ROI in six months, that’s your headline.
Align your sales process with the customer’s “clinical trial.” Map out their decision-making journey from awareness to deployment.
Use social proof from early adopters. Every deal closed is a data point that builds credibility.

Principle 3: Shorten the Sales Cycle with Pre-Clinical Validation

The longest part of any B2B sales cycle is the “ramp-up” period—where prospects need to get educated. Unicycive solves this by engaging key opinion leaders (KOLs) early, getting their endorsement, and publishing data. This pre-validation shortens the time from first meeting to contract.

For tech companies, this translates to:

Create a “credibility layer” before the demo. This can be white papers, webinars, or analyst reports.
Leverage existing relationships. Use referrals from your network to warm up cold outreach.
Build a champion program. Identify mid-market customers willing to provide testimonials or participate in co-marketing.

The CEO’s Role in Sales: Why Dr. Gupta’s Approach Works

From Scientist to Sales Leader

Moira Forbes’ interview touched on a critical point: the founder-CEO’s direct involvement in the sales process. Dr. Gupta didn’t delegate the GTM strategy to a VP of Sales immediately. He was in the trenches, pitching to venture capitalists, partners, and eventually, healthcare providers.

This is a playbook for early-stage B2B companies. When you’re scaling from $0 to $5M ARR, the CEO is often the best salesperson. They can answer the “why” questions no one else can.

The Risks and Rewards

The challenge? As the company grows, the CEO can’t stay in sales forever. At Unicycive, Dr. Gupta likely transitioned to a more strategic role, hiring specialized revenue leadership. For your team, the key is to know when to hand off the baton.

Signs It’s Time to Hire a VP of Sales:

You’re spending more than 50% of your time on deal management.
You have more inbound leads than you can handle.
Your sales process is no longer a “founder whisper”—it needs repeatable systems.

Revenue Strategy: The Unicycive Way to Build a Repeatable GTM Machine

Step 1: Define Your “Regulatory Pathway” for Sales

In biotech, every product must pass FDA approval. In B2B tech, every product must pass the “buyer approval” process. That means mapping out your prospect’s decision-making journey.

Create a “Buyer Journey Map”:

Awareness: How do they discover your problem exists?
Evaluation: How do they compare solutions?
Decision: Who needs to sign off?
Implementation: What does success look like post-purchase?

Step 2: Build a “Clinical Trial” for Your GTM

Unicycive’s clinical trials are expensive and time-consuming, but they provide rigorous data. Your GTM experiments should be similarly disciplined. Run A/B tests on your cold email sequences, landing pages, and pricing tiers.

Experiment Framework:

Hypothesis: “If we send a personalized video call-to-action, response rates will increase by 20%.”
Test: Run 100 cold emails with video vs. 100 without.
Measure: Track open rate, reply rate, and meetings booked.
Scale: Implement the winner across your entire outreach.

Step 3: Use “Key Opinion Leaders” for Sales Enablement

In healthcare, a doctor’s endorsement from a respected KOL can make or break a product. In tech, that KOL is your industry influencer, an analyst from Forrester or Gartner, or a well-connected customer.

How to Activate KOLs:

Co-create content. Write a LinkedIn article together or host a joint webinar.
Offer early access. Get their feedback on your product roadmap.
Leverage their network. Need an intro to a key decision-maker? Ask for it.

The Metrics That Matter in Biotech (and B2B)

Dr. Gupta’s success at Unicycive isn’t just about science; it’s about measurement. Here are the revenue metrics he likely tracks—and how they apply to you:

Biotech Metric	B2B Equivalent	Why It Matters
Clinical trial enrollment	Demo conversion rate	Indicates product-market fit
FDA approval timeline	Sales cycle length	Predicts revenue predictability
KOL endorsement	Customer referral rate	Drives lower CAC
Patient adherence	User retention/churn	Determines LTV
Reimbursement / pricing	ARR per account	Reveals pricing power

Action: Start tracking your “clinical trial” metrics. If you don’t have a dashboard for sales cycle length, create one today.

Conclusion: The Future of Growth Is Precision Medicine for Revenue

The Unicycive Therapeutics story is a powerful reminder that growth is not a one-size-fits-all play. Whether you’re launching a new drug or a new SaaS platform, the principles remain the same: focus on a specific problem, use data to build credibility, and execute with surgical precision.

As Dr. Gupta told Moira Forbes, the path forward for Unicycive involves continuing to innovate while maintaining operational discipline. For your revenue team, that means:

Narrow your focus.
Shorten your sales cycle.
Build a GTM engine that’s as rigorous as a clinical trial.

At B2B Pulse, we’ll be watching how Unicycive scales from here. The biotech playbook is too powerful to ignore. Steal it. Optimize it. Apply it to your tech stack.

Ready to accelerate your own revenue growth? Start by auditing one metric from the table above this week. DM me your biggest bottleneck—we’ll help you build the solution.

Source: Forbes x Unicycive Therapeutics interview with Moira Forbes and Shalabh Gupta, M.D.

See also: